Older studies indicated that methotrexate, leflunomide, tacrolimus, gold salts, sulfasalazine, as well as anti‐tumor necrosis factor α (anti‐TNFα) and anti‐CD20 biologic agents exhibited the highest risk of ILD development [6, 7, 13, 22]. Here, TNF is linked to interstitial lung disease.